What women want. Women's preferences for the management of low-grade abnormal cervical screening tests: A systematic review

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 119, Issue 1, 2012, Pages 7-19

  Frederiksen, M E ^a   Lynge, E ^a   Rebolj, M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cervical cancer; follow up; low grade abnormal tests; preferences; screening

Indexed keywords

CANCER RISK; COLPOSCOPY; DYSKARYOSIS; FEMALE; FOLLOW UP; HUMAN; PAPANICOLAOU TEST; PATIENT PREFERENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHOICE BEHAVIOR; DISEASE MANAGEMENT; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATIENT PREFERENCE; RESEARCH DESIGN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 83655201386     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2011.03130.x     Document Type: Review

References (58)

1. International Agency for Research on Cancer (IARC). IARC Handbooks of Cancer Prevention, Vol. 10: Cervix Cancer Screening. Lyon: International Agency for Research on Cancer Press, 2005.
2. Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, et al., Process performance of cervical screening programmes in Europe. Eur J Cancer 2009; 45: 2659-70.
3. Rebolj M, van Ballegooijen M, Berkers LM, Habbema D,. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007; 120: 806-12. (Pubitemid 46175400)
4. Insinga RP, Glass AG, Myers ER, Rush BB,. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007; 27: 414-22. (Pubitemid 47106938)
5. Tombola Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial. Br Med J 2009; 339: b2546.
6. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-92.
7. Melnikow J, Nuovo J, Paliescheskey M,. Management choices for patients with "squamous atypia" on Papanicolaou smear. A toss up? Med Care 1996; 34: 336-47. (Pubitemid 126433239)
8. Tombola Group. Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. Br Med J 2009; 339: b2549.
9. Prendiville W, Walker P,. Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Clin Obstet Gynecol 1995; 38: 592-9.
10. Flannelly G, Kitchener H,. Every woman with an abnormal cervical smear should be referred for treatment: debate. Clin Obstet Gynecol 1995; 38: 585-91.
11. Jones MH, Singer A, Jenkins D,. The mildly abnormal cervical smear: patient anxiety and choice of management. J R Soc Med 1996; 89: 257-60. (Pubitemid 26174501)
12. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A,. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. Br Med J 2004; 328: 1293.
13. Melnikow J, Birch S,. Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost? J Natl Cancer Inst 2006; 98: 82-3. (Pubitemid 43159955)
14. Ferris DG, Kriegel D, Cote L, Litaker M, Woodward L,. Women's triage and management preferences for cervical cytologic reports demonstrating atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions. Arch Fam Med 1997; 6: 348-53. (Pubitemid 127439277)
15. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al., Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26: K29-41.
16. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al., Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72. (Pubitemid 350137476)
17. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del MA, et al., Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
18. Lynge E, Rebolj M,. Primary HPV screening for cervical cancer prevention: results from European trials. Nat Rev Clin Oncol 2009; 6: 699-706.
19. Peters T, Somerset M, Baxter K, Wilkinson C,. Anxiety among women with mild dyskaryosis: a randomized trial of an educational intervention. Br J Gen Pract 1999; 49: 348-52. (Pubitemid 29237597)
20. Huang AJ, Perez-Stable EJ, Kim SE, Wong ST, Kaplan CP, Walsh JM, et al., Preferences for human papillomavirus testing with routine cervical cancer screening in diverse older women. J Gen Intern Med 2008; 23: 1324-9.
21. McCaffery KJ, Irwig L, Chan SF, Macaskill P, Barratt A, Lewicka M, et al., HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: evaluation of a decision aid to support informed choice. Patient Educ Couns 2008; 73: 473-81.
22. Whynes DK, Woolley C, Philips Z,. Management of low-grade cervical abnormalities detected at screening: which method do women prefer? Cytopathology 2008; 19: 355-62.
23. Howard K, Salkeld G, McCaffery K, Irwig L,. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ 2008; 17: 593-605. (Pubitemid 351772340)
24. Melnikow J, Kuppermann M, Birch S, Chan BK, Nuovo J,. Management of the low-grade abnormal Pap smear: what are women's preferences? J Fam Pract 2002; 51: 849-55.
25. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al., ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009; 13: i-iv.
26. Meana M, Stewart DE, Lickrish GM, Murphy J, Rosen B,. Patient preference for the management of mildly abnormal Papanicolaou smears. J Womens Health Gend Based Med 1999; 8: 941-7. (Pubitemid 29501938)
27. Brown L, Ritvo P, Howlett R, Cotterchio M, Matthew A, Rosen B, et al., Attitudes toward HPV testing: interview findings from a random sample of women in Ontario, Canada. Health Care Women Int 2007; 28: 782-98.
28. Philips Z, Avis M, Whynes DK,. Introducing HPV triage into the English cervical cancer screening program: consequences for participation. Women Health 2006; 43: 17-34. (Pubitemid 44523772)
29. Kitchener HC, Burns S, Nelson L, Myers AJ, Fletcher I, Desai M, et al., A randomised controlled trial of cytological surveillance versus patient choice between surveillance and colposcopy in managing mildly abnormal cervical smears. BJOG 2004; 111: 63-70. (Pubitemid 38223335)
30. Le T, Hicks W, Menard C, Boyd D, Hewson T, Hopkins L, et al., Human papilloma virus testing knowledge and attitudes among women attending colposcopy clinic with ASCUS/LGSIL pap smears. J Obstet Gynaecol Can 2004; 26: 788-92.
31. Patel M, Guido R, Chang JC, Meyn LA,. What are patient preferences for follow-up after low-grade cervical intraepithelial neoplasia? J Low Genit Tract Dis 2008; 12: 122-6. (Pubitemid 351457918)
32. Orbell S, Hagger M, Brown V, Tidy J,. Appraisal theory and emotional sequelae of first visit to colposcopy following an abnormal cervical screening result. Br J Health Psychol 2004; 9: 533-55. (Pubitemid 39487262)
33. Wordsworth S, Ryan M, Skatun D, Waugh N,. Women's preferences for cervical cancer screening: a study using a discrete choice experiment. Int J Technol Assess Health Care 2006; 22: 344-50. (Pubitemid 44469441)
34. McCaffery K, Irwig L,. Australian women's needs and preferences for information about human papillomavirus in cervical screening. J Med Screen 2005; 12: 134-41. (Pubitemid 41337146)
35. Naik R, Abang-Mohammed K, Tjalma WA, Nordin A, de Barros LA, Cross PA, et al., The feasibility of a one-stop colposcopy clinic in the management of women with low grade smear abnormalities: a prospective study. Eur J Obstet Gynecol Reprod Biol 2001; 98: 205-8. (Pubitemid 33713893)
36. Lonky NM, Hunter MI, Sadeghi M, Edwards G, Bajamundi K, Monk BJ,. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program. J Low Genit Tract Dis 2007; 11: 258-64. (Pubitemid 47530913)
37. Basen-Engquist K, Fouladi RT, Cantor SB, Shinn E, Sui D, Sharman M, et al., Patient assessment of tests to detect cervical cancer. Int J Technol Assess Health Care 2007; 23: 240-7. (Pubitemid 46642721)
38. Kavanagh AM, Broom DH,. Women's understanding of abnormal cervical smear test results: a qualitative interview study. Br Med J 1997; 314: 1388-91. (Pubitemid 27192927)
39. Birch S, Melnikow J, Kuppermann M,. Conservative versus aggressive follow up of mildly abnormal Pap smears: testing for process utility. Health Econ 2003; 12: 879-84. (Pubitemid 37220638)
40. Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J,. Women's experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. Psychooncology 2007; 16: 196-204. (Pubitemid 46380543)
41. McCaffery KJ, Irwig L, Turner R, Chan SF, Macaskill P, Lewicka M, et al., Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. Br Med J 2010; 340: b4491.
42. Hartz LE, Fenaughty AM,. Management choice and adherence to follow-up after colposcopy in women with cervical intraepithelial neoplasia 1. Obstet Gynecol 2001; 98: 674-9. (Pubitemid 32907466)
43. Philips Z, Avis M, Whynes DK,. Knowledge of cervical cancer and screening among women in east-central England. Int J Gynecol Cancer 2005; 15: 639-45. (Pubitemid 41022902)
44. Kjaer SK, Frederiksen K, Munk C, Iftner T,. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-88.
45. Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P,. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. Int J Gynecol Cancer 2008; 18: 743-8. (Pubitemid 352020187)
46. McCaffery K, Forrest S, Waller J, Desai M, Szarewski A, Wardle J,. Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK. Br J Cancer 2003; 88: 42-6. (Pubitemid 36241216)
47. McCaffery K, Waller J, Nazroo J, Wardle J,. Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex Transm Infect 2006; 82: 169-74.
48. Perrin KK, Daley EM, Naoom SF, Packing-Ebuen JL, Rayko HL, McFarlane M, et al., Women's reactions to HPV diagnosis: insights from in-depth interviews. Women Health 2006; 43: 93-110. (Pubitemid 44523776)
49. Conaglen HM, Hughes R, Conaglen JV, Morgan J,. A prospective study of the psychological impact on patients of first diagnosis of human papillomavirus. Int J STD AIDS 2001; 12: 651-8. (Pubitemid 32964349)
50. NHS Cervical Screening Programme. Cervical Screening: Pocket Guide. 2009. []. Last accessed 2 May 2011.
51. NHS Cervical Screening Programme. HPV Sentinel Sites Implementation Project. 2010. []. Last accessed 1 June 2011.
52. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D,. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-55. (Pubitemid 47464164)
53. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A,. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer 2005; 92: 990-4. (Pubitemid 40546658)
54. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al., Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88-99.
55. Sharp L, Cotton S, Cochran C, Gray N, Little J, Neal K, et al., After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG 2009; 116: 1506-14.
56. Rebolj M, Bonde J, Njor SH, Lynge E,. Human papillomavirus testing in primary cervical screening and the cut-off for Hybrid Capture 2 tests: systematic review. Br Med J 2011; 342: d2757.
57. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Halfon P, et al., Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2010; 129: 691-701.
58. Kim SE, Perez-Stable EJ, Wong S, Gregorich S, Sawaya GF, Walsh JM, et al., Association between cancer risk perception and screening behavior among diverse women. Arch Intern Med 2008; 168: 728-34. (Pubitemid 351563956)